<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOBUTAMINE HYDROCHLORIDE</span><br/>(doe-byoo'ta-meen)<br/><span class="topboxtradename">Dobutrex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic agonist</span>; <span class="classification">catecholamine</span><br/><b>Prototype: </b>Isoproterenol<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>12.5 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Produces inotropic effect by acting on beta receptors and primarily on myocardial alpha-adrenergic receptors. Increases cardiac
         output and decreases pulmonary wedge pressure and total systemic vascular resistance with comparatively little or no effect
         on BP. Also increases conduction through AV node. Has lower potential for precipitating arrhythmias than dopamine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In CHF or cardiogenic shock, increase in cardiac output enhances renal perfusion and increases renal output and renal sodium
         excretion.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Inotropic support in short-term treatment of adults with cardiac decompensation due to depressed myocardial contractility
         (cardiogenic shock) resulting from either organic heart disease or from cardiac surgery.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To augment cardiovascular function in children undergoing cardiac catheterization, stress thallium testing.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to other sympathomimetic amines, ventricular tachycardia, idiopathic hypertrophic subaortic stenosis.
         Safe use during pregnancy (category C), lactation, children, or following acute MI is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Preexisting hypertension, atrial fibrillation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cardiac Decompensation</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 2.510 mcg/kg/min (max: 40 mcg/kg/min), has been given for up to 72 h without decrease in effectiveness<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Continuous:</span>  Reconstitute by adding 10 mL sterile water for injection or D5W to 250-mg vial; if not completely dissolved, add an additional
                  10 mL of diluent. Further dilute to a volume of at least 50 mL with D5W, NS, LR, D5/LR, or sodium lactate injection. Use IV solutions within 24 h. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span>  Rate of infusion is determined by body weight and controlled by an infusion pump (preferred) or a microdrip IV infusion set. IV infusion rate and duration of therapy are determined by heart rate, blood pressure, ectopic activity, urine output, and
                  whenever possible, by measurements of cardiac output and central venous or pulmonary wedge pressures. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Sodium bicarbonate,</b> <b>aminophylline,</b> <b>bretylium,</b> <b>bumetanide,</b> <b>calcium chloride,</b> <b>calcium gluconate,</b> <b>diazepam,</b> <b>doxapram,</b> <b>digoxin,</b> <b>epinephrine,</b> <b>furosemide,</b> <b>heparin,</b> <b>insulin,</b> <b>magnesium sulfate,</b> <b>nitroprusside sodium, phenytoin,</b> <b>potassium chloride,</b> <b>potassium phosphate.</b> <span class="incompattype">Y-site:</span> <b>Acyclovir,</b> <b>aminophylline,</b> <b>sodium bicarbonate.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Refrigerate reconstituted solution at 2°15° C (36°59° F) for 48 h or store for 6 h at room
            temperature.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">All:</span> Generally dose related. <span class="typehead">CNS:</span> Headache, tremors, paresthesias, mild leg cramps, nervousness, fatigue (with overdosage). <span class="typehead">CV:</span> <span class="speceff-common">Increased heart rate and BP,</span> premature ventricular beats, palpitation, <span class="speceff-common">anginal pain</span>. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Other:</span> Nonspecific chest pain, shortness of breath. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">general anesthetics</span> (especially <b>cyclopropane</b> and <b>halothane</b>) may sensitize myocardium to effects of <span class="classification">catecholamines</span> such as dobutamine and lead to serious arrhythmiasused with extreme caution; <span class="classification">beta-adrenergic blocking agents</span>, e.g., <b>metoprolol,</b> <b>propranolol,</b> may make dobutamine ineffective in increasing cardiac output, but total peripheral resistance may increaseconcomitant
      use generally avoided; <span class="classification">mao inhibitors</span>, <span class="classification">tricyclic antidepressants</span> potentiate pressor effectsuse with extreme caution. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 210 min. <span class="typehead">Peak:</span> 1020 min. <span class="typehead">Metabolism:</span> Metabolized in liver and other tissues by COMT. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 2 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Correct hypovolemia by administration of appropriate volume expanders prior to initiation of therapy.</li>
<li>Monitor therapeutic effectiveness. At any given dosage level, drug takes 1020 min to produce peak effects.</li>
<li>Monitor ECG and BP continuously during administration.</li>
<li> 								Note: Marked increases in blood pressure (systolic pressure is the most likely to be affected) and heart rate, or the appearance
            of arrhythmias or other adverse cardiac effects are usually reversed promptly by reduction in dosage. 							
         </li>
<li>Observe patients with preexisting hypertension closely for exaggerated pressor response.</li>
<li> 								Note: Tolerance has been observed with continuous or prolonged infusions; adverse reactions are no different than those seen with
            shorter infusions. 							
         </li>
<li>Monitor I&amp;O ratio and pattern. Urine output and sodium excretion generally increase because of improved cardiac output and
            renal perfusion.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report anginal pain to physician promptly.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>